takisbiotech
Menu
Close
Company
About Us
Our Team
Careers
Our Services
Vaccines & Preclinical Immunology
Predictive Models
Monoclonal Antibodies
Recombinant Proteins
Facilities
BSL-3
GMP
Research
Funded Projects
Internal Research
Papers
Congresses
News
Contact Us
Company
About Us
Our Team
Careers
Our Services
Vaccines & Preclinical Immunology
Predictive Models
Monoclonal Antibodies
Recombinant Proteins
Facilities
BSL-3
GMP
Research
Funded Projects
Internal Research
Papers
Congresses
News
Contact Us
Company news
Stay updated with Takis latest news!
Dynamics of humoral and cellular response to three doses of the anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
February 6, 2024
|
News
|
Vitares in the Spera Federation
January 25, 2024
|
News
|
National Center for mRNA and Gene Therapies
January 22, 2024
|
News
|
Takis was among the winners of the Open Infrastructures for Research 2022 tender by Lazio Innova
January 16, 2024
|
News
|
Isolation and Characterization of Neutralizing Monoclonal Antibodies Against RBD of the SARS-CoV-2 Spike Protein
January 10, 2024
|
News
|
Takis biotech is at the forefront of the development of solutions against pathogens with high epidemic/pandemic potential.
May 7, 2023
|
News
|
COVID-eVax PHASE 1 CLINICAL TRIAL RESULTS PUBLISHED
January 7, 2023
|
News
|
Takis is glad to announce the promotion of Giuseppe Roscilli and Emanuele Marra in their new roles.
January 1, 2023
|
News
|
BIO International Convention
June 7, 2022
|
News
|
1
2
3
4
